Keywords: AstraZeneca, Brilinta, USA, FDA, PUDFA, Blood thinner

New PDUFA date for AstraZeneca’s Brilinta in the USA

Article | 04 February 2011

Print This

In another delay for the approval of Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) potentially blockbuster blood thinner Brilinta ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in